129 related articles for article (PubMed ID: 7227419)
1. Achievement of long duration methotrexate exposure with concurrent low dose thymidine protection: influence of methotrexate pharmacokinetics.
Howell SB; Tamerius RK
Eur J Cancer (1965); 1980 Nov; 16(11):1427-32. PubMed ID: 7227419
[No Abstract] [Full Text] [Related]
2. The prevention of methotrexate toxicity by thymidine infusions in humans.
Ensminger WD; Frei E
Cancer Res; 1977 Jun; 37(6):1857-63. PubMed ID: 870189
[TBL] [Abstract][Full Text] [Related]
3. Thymidine rescue of high-dose methotrexate in humans.
Howell SB; Ensminger WD; Krishan A; Frei E
Cancer Res; 1978 Feb; 38(2):325-30. PubMed ID: 637906
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of high-dose methotrexate with thymidine and low-dose leucovorin.
Bruno S; Grindey G; Zakrzewski S; Priore R; Kinahan J; Moayeri H; Ledesma E; Mittelman A; Creaven P
Cancer Res; 1982 Nov; 42(11):4824-6. PubMed ID: 6982097
[TBL] [Abstract][Full Text] [Related]
5. Potentiation of the antitumor activity of methotrexate by concurrent infusion of thymidine.
Semon JH; Grindey GB
Cancer Res; 1978 Sep; 38(9):2905-11. PubMed ID: 679199
[No Abstract] [Full Text] [Related]
6. A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue.
Stoller RG; Kaplan HG; Cummings FJ; Calabresi P
Cancer Res; 1979 Mar; 39(3):908-12. PubMed ID: 311683
[No Abstract] [Full Text] [Related]
7. Methotrexate with thymidine protection or rescue in advanced head and neck cancer: a phase II study.
Schornagel JH; Leyva A; Pinedo HM
Cancer Treat Rep; 1984 Mar; 68(3):543-5. PubMed ID: 6704983
[No Abstract] [Full Text] [Related]
8. Methotrexate with thymidine, inosine, and allopurinol rescue: a phase I clinical study.
Dady PJ; Taylor GA; Muindi JF; Calvert AH; Smith IE; Smyth JF; Harrap KR
Cancer Treat Rep; 1981; 65 Suppl 1():37-43. PubMed ID: 7326664
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
[TBL] [Abstract][Full Text] [Related]
10. Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine.
Abelson HT; Fosburg MT; Beardsley GP; Goorin AM; Gorka C; Link M; Link D
J Clin Oncol; 1983 Mar; 1(3):208-16. PubMed ID: 6607976
[TBL] [Abstract][Full Text] [Related]
11. Modulation versus rescue of antimetabolite toxicity by salvage metabolites administered by continuous infusion.
Grindey GB; Semon JH; Pavelic ZP
Antibiot Chemother (1971); 1978; 23():295-304. PubMed ID: 306219
[TBL] [Abstract][Full Text] [Related]
12. High-dose methotrexate-citrovorum factor rescue in the management of brain tumors.
Djerassi I; Kim JS; Shulman K
Cancer Treat Rep; 1977 Jul; 61(4):691-4. PubMed ID: 301782
[No Abstract] [Full Text] [Related]
13. Clinical use of thymidine as a rescue agent from methotrexate toxicity.
Grem JL; King SA; Sorensen JM; Christian MC
Invest New Drugs; 1991 Aug; 9(3):281-90. PubMed ID: 1838364
[TBL] [Abstract][Full Text] [Related]
14. Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction.
Widemann BC; Balis FM; Murphy RF; Sorensen JM; Montello MJ; O'Brien M; Adamson PC
J Clin Oncol; 1997 May; 15(5):2125-34. PubMed ID: 9164227
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of 24-hour infusion of high-dose methotrexate--pharmacokinetics and toxicity.
Goh TS; Wong KY; Lampkin B; O'Leary J; Gnarra D
Cancer Chemother Pharmacol; 1979; 3(3):177-80. PubMed ID: 316745
[TBL] [Abstract][Full Text] [Related]
16. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
Chiuten DF; Miller A; Valdivieso M; Loo TL; Bedikian A; Bodey GP; Benvenuto JA; Freireich EJ
Am J Clin Oncol; 1985 Aug; 8(4):332-5. PubMed ID: 4083263
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.
Cohen HJ; Jaffe N
Cancer Chemother Pharmacol; 1978; 1(1):61-4. PubMed ID: 373909
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of high-dose methotrexate with modified citrovorum factor rescue.
Jacobs SA; Santicky MJ
Cancer Treat Rep; 1978 Mar; 62(3):397-9. PubMed ID: 348306
[No Abstract] [Full Text] [Related]
19. Clinical trials and pharmacokinetics of intermittent high-dose methotrexate-"leucovorin rescue" for children with malignant tumors.
Pratt CB; Roberts D; Shanks EC; Warmath EL
Cancer Res; 1974 Dec; 34(12):3326-31. PubMed ID: 4547680
[No Abstract] [Full Text] [Related]
20. Thymidine requirements for the rescue of patients treated with high-dose methotrexate.
Howell SB; Herbst K; Boss GR; Frei E
Cancer Res; 1980 Jun; 40(6):1824-9. PubMed ID: 7371013
[No Abstract] [Full Text] [Related]
[Next] [New Search]
